Navigation Links
Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Company's New U.S. Headquarters

PLAINSBORO, N.J., Aug. 1, 2011 /PRNewswire/ -- Diabetes company Novo Nordisk, Inc., and a joint venture led by Ivy Equities and LCOR in partnership with Intercontinental Real Estate Corporation, today announced a $215 million redevelopment project to completely renovate and upgrade a 770,000-square-foot office building in the Princeton Forrestal Center in Plainsboro, N.J., that will serve as the new U.S. headquarters for the Danish pharmaceutical company.

(Photo: )

"The decision by Novo Nordisk to maintain its American Headquarters in Plainsboro and move into a new building is positive economic news for the state," said Governor Chris Christie. "This project, for one of the world's premier life sciences companies, clearly demonstrates that the fiscal and regulatory reforms we have implemented in New Jersey are fostering an environment conducive to growth, business expansion and job creation. I applaud Novo Nordisk for their continued commitment to the Garden State."

The company has signed a long-term lease for the entire building, with the initial phase of occupancy being approximately 500,000 square feet and the option to take the balance of the space within the building at any time. The deal represents New Jersey's largest commercial real estate transaction this year. Construction on the redevelopment, which will create more than 500 union construction jobs, is scheduled to begin in September. The building is located at 800 Scudders Mill Road and will be able to accommodate approximately 1,500 employees.

Novo Nordisk will be relocating from its existing headquarters at 100 College Road West in Princeton, and plans to occupy its new space in spring 2013 upon completion of the full-scale rehabilitation. Novo Nordisk's initial lease at the new building will expand its presence in the Princeton-area market by approximately 150,000 square feet.

"This move reflects Novo Nordisk's growth in the U.S., and our efforts in delivering leading therapies to diabetes patients and their healthcare providers," said Jerzy Gruhn, President, Novo Nordisk, Inc. "This smart renovation keeps us in New Jersey, reduces the impact on our employees as well as the environment, and allows us to meet the expanding need for our medicines."

Anthony P. DiTommaso, Jr., Co-Chief Executive Officer of Ivy Equities, stated, "We have assembled a world-class development team with nationally recognized LCOR and Intercontinental Real Estate Corporation to deliver a best-in-class headquarters location for Novo Nordisk that will effectively support the company's business objectives and provide its employees with a sustainable, technologically advanced work environment."

LCOR and Ivy Equities will execute a top-to-bottom, gut rehabilitation of the property that will strip the vintage 1985 building to its skeletal frame. The plans include replacement of the building's façade, roof, interiors and mechanical systems, and attainment of LEED certification for the building from the U.S. Green Building Council. The renovated property will feature state of-the-art electrical and mechanical systems. Granum A/I is the project's exterior design architect, while HOK is serving as the architect of record.

"This exciting, new American headquarters for Novo Nordisk will reaffirm New Jersey's status as the capital of the country's pharmaceutical industry," said LCOR executive vice president Kurt M. Eichler. "Desiring to relocate to an in-state, Class A facility, the company had explored the option of occupying a ground-up, build-to-suit building at another location. But Novo Nordisk soon recognized the enhanced value of the adaptive re-use approach presented by Ivy Realty, LCOR and Intercontinental."

Peter Palandjian, Chief Executive Officer of Intercontinental, stated, "We are thrilled to partner with Ivy and LCOR, which are experienced, first-rate real estate firms. This is an uncommon deal in these challenging markets; a value-add construction deal that is de-risked on the way in, and a construction project that is 'core' before we even start. Our tenant, Novo Nordisk, is world class and the market leader in its space. The company's long-term commitment to the property makes this deal possible. It is especially exciting for Intercontinental because of our union investors, who truly stepped up for this project."

After a full search process including some of the leading real estate investment firms, the Northeast Regional Council of Carpenters (NRCC) hired Intercontinental in 2010 to manage a portion of the union's pension investments in a strategic program that would invest in value-added and construction projects in New Jersey and the surrounding states, where they represent 30,000 members. "In these difficult economic times, I am glad that carpenters are investing capital funds to help finance this project," said Michael Capelli, Executive Secretary-Treasurer of the Northeast Regional Council of Carpenters. "Not only will this construction project create union jobs for NRCC members, the investment will strengthen our members' pension and annuity portfolios. It is good long-term financial strategy that provides excellent short-term benefits." To date, in addition to the Carpenters lead investment of $55 million, the New Jersey Laborers and the New Jersey Operating Engineers have also invested with Intercontinental for a combined amount of approximately $100 million.

Plainsboro Mayor Peter Cantu added, "We are delighted that Novo Nordisk has made the decision to remain and expand its presence in Plainsboro with a development project that will create jobs and deliver a high-quality building to our township. Novo Nordisk continues to be a great corporate citizen, and we thank them, as well as the ownership of this property, for investing in Plainsboro's bright future."

Steven Tolkach of Newmark Knight Frank represented the leasing efforts on behalf of Novo Nordisk. Sovereign/Santander and Wells Fargo banks served as co-agents for the development financing. Holliday Fenoglio Fowler, under the leadership of senior managing director Andrew Scandalios, arranged the joint venture equity and construction financing for the development.

"Today is a tremendous day for New Jersey's economic future," added DiTommaso. "We are creating more than 500 construction jobs, bringing new life to a vacant office building, and retaining a highly regarded pharmaceutical company and its high-paying jobs here in New Jersey. We are proud to be executing on our vision for this remarkable property, and look forward to transforming this building into a vibrant, state-of-the-art corporate headquarters for Novo Nordisk."

About Novo Nordisk

Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 88 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit

About Ivy Realty

Ivy Realty was founded in 1996 to acquire commercial real estate in the northeastern United States. Since its inception, Ivy has built a reputation as one of the finest real estate operators in the tri-state market having acquired over $1 billion in commercial real estate assets. Today, Ivy Realty is a full service real estate company offering asset management, property management, accounting, construction and leasing services.

About LCOR

LCOR Incorporated is a national real estate development, investment and management company.  The firm develops multifamily, commercial and mixed-use projects, with specialized expertise in public-private real estate initiatives and transit-oriented development. With projects throughout the United States, LCOR has more than $8 billion in developments completed, under construction or in pre-development. LCOR has created more than 16 million square feet of commercial space and more than 20,000 residential units nationally.

About Intercontinental Real Estate Corporation

Intercontinental Real Estate Corporation is an SEC-Registered Investment Adviser that manages private equity real estate investments and provides real estate services for domestic and international clients. Established in Boston over 50 years ago, Intercontinental has acquired, developed, managed, and owned over US $6 billion of real estate assets across all property types. Presently, Intercontinental owns and manages a portfolio in excess of $2.4 billion for its clients and is actively seeking opportunities to invest in core, core plus as well as value oriented development projects.

SOURCE Ivy Equities
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novo Nordisk A/S: PharmaVitae Profile
2. Video from Novo Nordisk A/S available on Novo Nordisk Receives Approval for Victoza in China
3. Novo Nordisk Submits First Recombinant Treatment for Factor XIII Deficiency for U.S. Regulatory Approval
4. Novo Nordisk Creates First Mobile Application to Help Doctors Diagnose Bleeding Disorders
5. Novo Nordisk Intends to Appeal Adverse Ruling in Prandin® (repaglinide) Patent Case
6. Reportlinker Adds Novo Nordisk A/S: PharmaVitae Profile
7. Novo Nordisk A/S and Emisphere Technologies, Inc. Announce License Agreement to Develop Oral Formulation of Insulin for Diabetes
8. Novo Nordisk and Chip Ganassi Racing Team Up for 2011 IZOD IndyCar Series
9. Novo Nordisk and Entertainment Industries Council Work Together to Improve Public Education and Awareness about Diabetes Epidemic
10. Novo Nordisk to Invest $73m in Expansion of U.S. Manufacturing Facility
11. Novo Nordisk Inc. Announces Exclusive Agreement With Upsher-Smith Laboratories, Inc. to Market Vagifem® 10 mcg
Post Your Comments:
(Date:7/12/2017)... 12, 2017  Eli Lilly and Company (NYSE: ... companies to resolve pending patent litigation in the U.S. District ... regarding the Cialis ® (tadalafil) unit dose patent. ... 2020. As part of the agreement, Cialis exclusivity is now ... "The unit dose patent for Cialis is valid ...
(Date:7/11/2017)...  Sysmex America, Inc., a leading provider of ... well as middleware information systems technology, today announced ... assurance easier and more risk free than manual ... the innovation that it delivers to the laboratory. ... processes to a new level with automated, continuous ...
(Date:7/10/2017)... Md. , July 10, 2017 The ... non-animal test methods, is the recipient of a VITROCELL® ... the PETA International Science Consortium. The device, which is ... used to expose human lung cells to airborne test ... IIVS will use the VITROCELL® system for testing combustible ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... SignatureCare Emergency Center ... be awarded for the fall semester to a deserving student. Get your applications ... 2017 scholarship was awarded to Mariana Castillo who is a nursing student at Prairie ...
(Date:7/24/2017)... Los Angeles, California (PRWEB) , ... July 24, ... ... office building fire in Oakland, California effectively destroyed the construction site and threatened ... to a July 7th article on Los Angeles Area ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , ... announced it has partnered with WALLIX to expand its solution to help ... , There are a number of ways to address the authentication requirements within ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the global ... the issuance of United States Patent Number 9,695,398 (the '398 patent) and South ... The '398 and '324 patents cover methods and systems for optimizing fat grafts ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
Breaking Medicine News(10 mins):